NASDAQ · RAPP
Rapport Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for RAPP: Nov 5, 2026
Rapport Therapeutics, Inc. Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.21. The reported EPS for the same quarter last year was $-0.71.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.21 | $-1.02 | $-1.36 | 5 |
| Dec 2026 | $-1.19 | $-0.99 | $-1.54 | 5 |
| Mar 2027 | $-1.27 | $-1.03 | $-1.63 | 3 |
| Jun 2027 | $-1.29 | $-0.99 | $-1.68 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · MarketBeat · Fintel · BNK Invest- RTTNews · Oct 28, 10:36 AM EDTRapport Therapeutics Prices $380 Million Stock And Convertible Notes Offerings; Stock Down(RTTNews) – Rapport Therapeutics, Inc. (RAPP) announced the pricing of separate public offerings of common stock and convertible senior notes, along with a concurrent private placement, with the transactions expected to raise approximately $380 million in gross proceeds before fe
- RTTNews · Oct 28, 2:27 AM EDTRapport Therapeutics Launches $350 Mln Stock And Convertible Notes Offerings; Stock Down(RTTNews) – Rapport Therapeutics, Inc. (RAPP), a clinical-stage biotechnology company, announced that it has commenced separate underwritten public offerings of $200 million of common stock and $150 million in aggregate principal amount of convertible senior notes due 2032.
- MarketBeat · Oct 25, 1:02 PM EDTRapport Therapeutics’ RAP-219 Hits Phase II Goals in Bipolar Mania TrialAnalysts Can't Get Enough of These Little-Known Biopharma StocksRapport Therapeutics (NASDAQ:RAPP) reported positive top-line results from a Phase II proof-of-concept trial of RAP-219 in adults with acute bipolar mania, meeting both its primary and secondary endpoints and support
- Fintel · Oct 23, 2:16 PM EDTRapport Therapeutics Consensus Price Target Increased by 10.79% to $69.65The average one-year price target for Rapport Therapeutics (NASDAQGM:RAPP) has been revised to $69.65 / share. This is an increase of 10.79% from the prior estimate of $62.87 dated September 29, 2026. These figures represent aggregate analyst targets compiled from multiple sourc
- BNK Invest · Oct 22, 10:43 AM EDTThursday 10/22 Insider Buying Report: FBK, RAPPAs the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy — they expect to make money. So let's look at two noteworthy recent insider buys. On Tuesday, FB Financial's Director, Orrin H. Ingram II, made a $1.54M purchase of
- BNK Invest · Oct 21, 4:44 PM EDTRapport Therapeutics Enters Oversold Territory (RAPP)Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me
- RTTNews · Oct 20, 6:46 AM EDTRapport's RAP-219 Meets Both Endpoints In Phase 2 Bipolar Mania Trial; Stock Surge 30% In Premarket(RTTNews) – On Tuesday, Rapport Therapeutics Inc. (RAPP) announced positive topline results from its Phase 2 trial of RAP-219 in adults with acute bipolar mania, meeting the primary and secondary endpoints and supporting the drug's advancement into Phase 3 development.
- Fintel · Oct 16, 8:23 PM EDTUBS Initiates Coverage of Rapport Therapeutics at BuyFintel reports that on October 15, 2026, UBS initiated coverage of Rapport Therapeutics (NASDAQGM:RAPP) with a Buy recommendation. This initiation occurred alongside another action on the same day, as Wolfe Research also initiated coverage on Rapport Therapeutics with an Outperfo
- BNK Invest · Oct 16, 3:55 PM EDTNotable Friday Option Activity: BA, RAPP, OLEDAmong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Boeing Co. (Symbol: BA), where a total of 85,652 contracts have traded so far, representing approximately 8.6 million underlying shares. That amounts to about 99.3% of B
- Fintel · Oct 15, 6:13 PM EDTWolfe Research Initiates Coverage of Rapport Therapeutics with Outperform RatingFintel reports that on October 15, 2026, Wolfe Research initiated coverage of Rapport Therapeutics (NASDAQGM:RAPP) with a Outperform recommendation. Prior to this rating action, the stock closed at $28.33 on October 14, 2026. This latest close represents a one-week price change o
- RTTNews · Sep 25, 7:28 AM EDTShow Me The Money: Rapport Stock Up Over 400% In 16 Months; Bipolar Mania Data Next(RTTNews) – Rapport Therapeutics Inc. (RAPP), a clinical-stage biotechnology company, has been steadily advancing its precision neuroscience pipeline, positioning itself as an increasingly notable contender in the evolving landscape of epilepsy treatment.
- BNK Invest · Sep 24, 5:05 PM EDTNotable Thursday Option Activity: SGHC, RAPP, BELooking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Super Group Ltd (Symbol: SGHC), where a total volume of 21,367 contracts has been traded thus far today, a contract volume which is representative of approximate
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Rapport Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.